Iovance Biotherapeutics Consensus Price Target Increased by 34.74% to $13.06
Published . Updated .
The average one-year price target for Iovance Biotherapeutics (NASDAQGM:IOVA) (DB:2LB) has been revised to $13.06 / share. This is an increase of 34.74% from the prior estimate of $9.69 dated September 11, 2026. These figures represent aggregate analyst targets compiled from mult
Directly affected
- IOVA Iovance Biotherapeutics
Named in this report.
Indirectly affected
- BTCZ T-Rex 2X Inverse Bitcoin Daily Target ETF
GA selected BTCZ as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DOGG FT VEST DJIA DOGS 10 TARGET INCOME ETF
GA selected DOGG as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- FGSI FT VEST GROWTH STRENGTH & TARGET INCOME ETF
GA selected FGSI as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ITDB ISHARES LIFEPATH TARGET DATE 2030 ETF
GA selected ITDB as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ITDC ISHARES LIFEPATH TARGET DATE 2035 ETF USD
GA selected ITDC as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
The average one-year price target for Iovance Biotherapeutics (NASDAQGM:IOVA) (DB:2LB) has been revised to $13.06 / share. This is an increase of 34.74% from the prior estimate of $9.69 dated September 11, 2026. These figures represent agg…
Source: Nasdaq Markets
Iovance Biotherapeutics (IOVA) since this story, compared with the market
Since the first closing price after “Iovance Biotherapeutics Consensus Price Target Increased by 34.74% to $13.06,” Iovance Biotherapeutics (IOVA) is +0.53%. The S&P 500 fund (SPY) is -1.08% over the same days, a +1.61% difference versus the market.
Who gains and who loses around Iovance Biotherapeutics (IOVA)
Companies tied to this story
- IOVA Iovance Biotherapeutics
Iovance Biotherapeutics (IOVA) is linked, with no stored direction, medium confidence in the 2 Oct 2026 story “Iovance Biotherapeutics Consensus Price Target Increased by 34.74% to $13.06.” Reason on file: GA selected IOVA as a RELATED security because its canonical security name directly matches this event's themes: biotherapeutics, iovance. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BTCZ T-Rex 2X Inverse Bitcoin Daily Target ETF
For “Iovance Biotherapeutics Consensus Price Target Increased by 34.74% to $13.06,” T-Rex 2X Inverse Bitcoin Daily Target ETF (BTCZ) is linked, with no stored direction, medium confidence. Reason on file: GA selected BTCZ as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DOGG Ft Vest Djia Dogs 10 Target Income Etf
For “Iovance Biotherapeutics Consensus Price Target Increased by 34.74% to $13.06,” Ft Vest Djia Dogs 10 Target Income Etf (DOGG) is linked, with no stored direction, medium confidence. Reason on file: GA selected DOGG as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- FGSI Ft Vest Growth Strength & Target Income Etf
Ft Vest Growth Strength & Target Income Etf (FGSI) is linked, with no stored direction, medium confidence in the 2 Oct 2026 story “Iovance Biotherapeutics Consensus Price Target Increased by 34.74% to $13.06.” Reason on file: GA selected FGSI as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ITDB Ishares Lifepath Target Date 2030 Etf
For “Iovance Biotherapeutics Consensus Price Target Increased by 34.74% to $13.06,” Ishares Lifepath Target Date 2030 Etf (ITDB) is linked, with no stored direction, medium confidence. Reason on file: GA selected ITDB as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ITDC Ishares Lifepath Target Date 2035 Etf Usd
For “Iovance Biotherapeutics Consensus Price Target Increased by 34.74% to $13.06,” Ishares Lifepath Target Date 2035 Etf Usd (ITDC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ITDC as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Iovance Biotherapeutics (IOVA)
The 2 Oct 2026 story “Iovance Biotherapeutics Consensus Price Target Increased by 34.74% to $13.06” names Iovance Biotherapeutics (IOVA) because of this story.
Iovance Biotherapeutics (IOVA) is on the page because GA selected IOVA as a RELATED security because its canonical security name directly matches this event's themes: biotherapeutics, iovance. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
T-Rex 2X Inverse Bitcoin Daily Target ETF (BTCZ) is here too. Its reason reads: GA selected BTCZ as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates and price levels for Iovance Biotherapeutics (IOVA)
BTCZ traded between 2.69 and 3.21 across 20 sessions. The latest close on file is 3.06. DOGG traded between 20.68 and 22.21 across 20 sessions. The latest close on file is 21.99. IOVA traded between 8.54 and 15.11 across 18 sessions. The latest close on file is 14.21.
How strong the case is around Iovance Biotherapeutics (IOVA)
46 out of 100
“Iovance Biotherapeutics Consensus Price Target Increased by 34.74% to $13.06” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.